Can Ureaplasma urealyticum Cause PID?
Yes, Ureaplasma urealyticum can cause pelvic inflammatory disease, though its role as a primary pathogen is controversial and likely limited compared to Chlamydia trachomatis and Neisseria gonorrhoeae.
Evidence for Causation
The relationship between U. urealyticum and PID is complex and not definitively established. While older CDC guidelines from 1991 acknowledge that "mycoplasmas have been recovered from the genital tract, but their role in PID is less clear" 1, more recent research provides mixed evidence:
Supporting Evidence
- Animal models demonstrate pathogenicity: A 2023 study successfully established a rat PID model using vaginal injection of U. urealyticum, showing inflammatory alterations, fallopian tube obstruction, edema, and adhesions with elevated inflammatory cytokines 2
- Clinical isolation from infected tissues: U. urealyticum has been isolated from the upper genital tract of women with PID, though at much lower rates than other pathogens 3, 4
- Severe infections in immunocompromised patients: Case reports document severe disseminated U. urealyticum infections including tubo-ovarian abscesses in immunosuppressed patients 5
- Bacteremia with pelvic infection: U. urealyticum has been isolated from blood cultures in women with postpartum and post-gynecological procedure pelvic infections 6
Contradicting Evidence
- Poor ascension to upper tract: U. urealyticum shows very limited propensity to spread from lower to upper genital tract, with a 31:1 ratio of cervical to tubal isolation (compared to 2.2:1 for C. trachomatis) 4
- Systematic review findings: A 2018 systematic review concluded that U. urealyticum "has a limited role as a pathogen" in PID, with most studies failing to demonstrate a clear association 7
- Questionable sole causation: In a longitudinal study, U. urealyticum appeared to be the sole cause in zero cases of PID, though it was detected in cervical specimens 3
Clinical Implications
Treatment Coverage
Current PID treatment regimens already provide coverage for U. urealyticum through doxycycline, which is included in all CDC-recommended regimens 1. The standard inpatient regimens include:
- Cefoxitin/cefotetan + doxycycline 100 mg every 12 hours, OR
- Clindamycin + gentamicin followed by doxycycline
Doxycycline remains effective against U. urealyticum and is the cornerstone of therapy for atypical organisms in PID 5.
Key Caveats
- Immunocompromised patients are at higher risk for severe U. urealyticum infections, particularly those with hypogammaglobulinemia 5
- U. urealyticum is commonly present as a commensal in the lower genital tract, making its detection not necessarily indicative of causation 4, 7
- Polymicrobial nature of PID: Most PID cases involve multiple organisms, making it difficult to establish U. urealyticum as a sole pathogen 1, 3
Bottom Line
While U. urealyticum can theoretically cause PID and has been isolated from infected upper genital tract tissues, it is a minor contributor compared to C. trachomatis and N. gonorrhoeae 1, 4, 7. Standard broad-spectrum PID treatment already covers this organism, so no specific modifications to therapy are needed based solely on concern for U. urealyticum. Consider it a potential co-pathogen in polymicrobial infections rather than a primary causative agent in immunocompetent women.